肥胖人群伏立康唑给药方案的系统评价

发布时间：2018-06-07 05:43

本文选题：伏立康唑 + 肥胖　；参考：《中国临床药理学杂志》2016年05期

【摘要】：目的研究肥胖人群伏立康唑的最佳给药方案。方法检索建库至2015年3月Pub Med、Em Base、Cochrane Library、Clinicaltrials.gov、中国知网、万方和中国生物医学文献数据库。比较肥胖人群不同给药方案或比较肥胖人群与非肥胖人群相应结局指标的文献。结果共纳入3篇队列研究,共237例。几种基于体重给药方案的肥胖患者和非肥胖患者安全性指标差异无统计学意义。没有研究报道感染治疗有效率。对于目标浓度达标率,基于调整体重(Adj BW)组显著高于基于实际体重(ABW)组和非肥胖人群组;对于随机血药浓度,在静脉给药时,实际体重(ABW)组显著高于非肥胖人群组(6.4 vs 2.8μg·m L~(-1));对于血药谷浓度,实际体重(ABW)显著高于非肥胖人群组(MD=2.70μg·m L~(-1))、基于理想体重(IBW)组(MD=2.25μg·m L~(-1))和调整体重(Adj BW)(MD=2.90μg·m L~(-1))。结论对于肥胖患者,推荐用基于调整体重(Adj BW)或理想体重(IBW)伏立康唑给药方案,并建议进行血药浓度监测。
[Abstract]:Objective to study the optimal regimen of voliconazole in obese population. Methods to search the database of Em Base Cochrane Library, China knowledge Network, Wanfang and Chinese Biomedical Literature Database until March, 2015. Literature comparing the outcome of different drug administration schemes in obese and non-obese groups. Results three cohort studies including 237 cases were included. There was no significant difference in the safety indexes between obese and non-obese patients based on weight administration regimen. No research has reported the effectiveness of infection treatment. For the target concentration, the Adj BW-based group was significantly higher than that of the actual body weight group and the non-obese group, and for the random blood concentration, the drug was administered intravenously. The actual body weight of ABW group was significantly higher than that of non-obese population group (6.4 vs 2.8 渭 g / L), and the actual body weight of ABW group was significantly higher than that of non-obese population group (MD2.70 渭 g / L, MD2.25 渭 g / L) and adjusted body weight (Adj BW)(MD=2.90 渭 g / L). Conclusion Veconazole based on Adj BW or IBW is recommended for obese patients, and blood concentration monitoring is recommended.
【作者单位】：北京大学第三医院药剂科;北京大学药学院药事管理与临床药学系;
【分类号】：R969

【相似文献】